Unicycive Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $675,000 | $951,000 | — |
| Operating income | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M |
| Operating expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M |
| Cash from operations | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Capital expenditure | $24,000 | $72,000 | $12,000 | $2,000 | $29,000 |
| Free cash flow | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M |
| Total assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M |
| Total liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M |
Shares outstanding 26.7M · Free float 74.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.